<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Thrombotic microangiopathy after kidney transplantation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Thrombotic microangiopathy after kidney transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Thrombotic microangiopathy after kidney transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anuja Java, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christophe Legendre, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Thrombotic microangiopathy (TMA) is characterized by mechanical hemolytic anemia, thrombocytopenia, and kidney function impairment. There are multiple etiologies for TMA. (See  <a class="medical medical_review" href="/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a>.)</p><p>TMA may result in end-stage kidney disease (ESKD), requiring either dialytic therapy or transplantation. Among patients with ESKD due to TMA who undergo transplantation, the risk of recurrence depends upon the underlying etiology. Less commonly, patients who undergo kidney transplantation for other causes of ESKD may also develop TMA.</p><p>This topic reviews de novo and recurrent TMA in kidney transplant recipients. The causes, diagnosis, and treatment of TMA in nontransplant patients are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1331.html" rel="external">"Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children"</a>.)</p><p></p><p class="headingAnchor" id="H454062462"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Most cases of TMA in the nontransplant population, particularly among children, are secondary to infection with Shiga toxin-producing <em>Escherichia coli</em> serotypes or <em>Streptococcus pneumoniae</em>. Other causes include pregnancy, cancer, autoimmune diseases (eg, systemic lupus erythematosus), metabolic issues (eg, cobalamin C/vitamin B12 deficiency), and medications (eg, <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a>, chemotherapeutic agents, and immunosuppressive drugs such as calcineurin inhibitors and mammalian [mechanistic] target of rapamycin [mTOR] inhibitors)  (<a class="graphic graphic_table graphicRef100722" href="/d/graphic/100722.html" rel="external">table 1</a>). TMA may also be caused by abnormal regulation of the alternative pathway of complement activation secondary to either loss-of-function mutations in regulators (factor H, factor I, and membrane cofactor protein) or gain-of-function mutations in activators (C3 and factor B) of the alternative pathway. In addition, complement-mediated TMA can occur by acquired factors including development of autoantibodies to complement proteins (eg, autoantibodies to factor H). (See  <a class="medical medical_review" href="/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children"</a>.)</p><p>TMA that occurs in the transplant recipient may be de novo or recurrent. Nearly all patients with recurrent TMA have a complement-mediated disease that produced both the pretransplant TMA and the recurrence after transplantation [<a href="#rid1">1</a>]. De novo TMA may be due to any of the etiologies that cause TMA in the general population or may be related to the transplantation. Causes of TMA that are more specific to transplant recipients include immunosuppressive drugs [<a href="#rid2">2,3</a>], ischemia reperfusion injury [<a href="#rid4">4</a>], viral infections, and antibody-mediated rejection (ABMR) [<a href="#rid5">5-8</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See <a class="local">'Epidemiology of de novo TMA'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>.)</p><p></p><p>Transplant recipients who develop de novo TMA in association with any of these exposures may also have a genetic susceptibility to the disease [<a href="#rid9">9,10</a>]. This was shown in a study of 24 transplant recipients with de novo TMA, of whom seven (29 percent) had a mutation in one or more of the genes encoding the complement-regulatory proteins, factor H, and factor I [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H2436323207"><span class="h2">Epidemiology of de novo TMA</span><span class="headingEndMark"> — </span>De novo TMA can affect 3 to 14 percent of kidney transplant recipients [<a href="#rid3">3,12-15</a>]. All of the causes of TMA that are present in the general population may affect the transplant recipient. (See  <a class="medical medical_review" href="/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a>.)</p><p>The following causes are of particular importance to the transplant recipient [<a href="#rid5">5,11,13,14,16-28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Medications including calcineurin inhibitors (<a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>), mammalian (mechanistic) target of rapamycin (mTOR) inhibitors (<a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>, <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>), and <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> (see  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infections including HIV, parvovirus B19, cytomegalovirus (CMV), coronavirus disease 2019 (COVID-19) [<a href="#rid29">29</a>], and others:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/6679.html" rel="external">"HIV-associated cytopenias", section on 'Other 'can't miss' diagnoses (TMAs, HLH, HHV8 disorders)'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/8272.html" rel="external">"Clinical manifestations and diagnosis of parvovirus B19 infection"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/8289.html" rel="external">"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'Venous thrombosis'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/127552.html" rel="external">"COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibody-mediated rejection (ABMR) (see  <a class="medical medical_review" href="/d/html/7352.html" rel="external">"Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection"</a>)</p><p></p><p class="headingAnchor" id="H1621410552"><span class="h2">Epidemiology of recurrent TMA</span><span class="headingEndMark"> — </span>Among all patients who have TMA as a cause of end-stage kidney disease (ESKD) and receive a kidney transplant, the recurrence rate is between 25 and 50 percent [<a href="#rid12">12,30-33</a>]. However, among individual patients, the risk depends upon the underlying cause of TMA in the native kidney. </p><p>Adults who develop TMA and are transplanted are more likely to have recurrence compared with children with hemolytic uremic syndrome (HUS) who receive a transplant [<a href="#rid31">31,34</a>]. In a single-center study of 35 kidney transplant recipients whose ESKD was caused by TMA, recurrence occurred in 10 of 17 adult-onset cases (59 percent) versus 1 of 18 (6 percent) with childhood TMA [<a href="#rid31">31</a>]. This observation is likely due to the fact that the vast majority (90 percent) of cases of childhood-onset TMA are related to Shiga toxin-producing <em>E. coli</em>, which recurs in &lt;1 percent of cases [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/6097.html" rel="external">"Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Long-term outcome'</a>.)</p><p>By contrast, many patients with complement-mediated TMA have recurrence after transplantation. Among such patients, the risk of recurrence depends upon the individual mutation [<a href="#rid10">10</a>]. Estimates of recurrence have been reported at 50 to 100 percent among patients with mutations involving circulating factors such as factor H or I and 15 to 20 percent among patients with mutations in the gene for the transmembrane protein, membrane cofactor protein (MCP, CD46) [<a href="#rid10">10</a>]. In addition, complement factor H (<em>CFH)</em> and complement factor I (<em>CFI)</em> mutations are more common than <em>MCP</em> mutations  (<a class="graphic graphic_table graphicRef87824" href="/d/graphic/87824.html" rel="external">table 2</a>). A review of published outcomes after transplant (prior to the availability of the C5 inhibitor, <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>) in patients with non-Shiga toxin-associated TMA genotyped for <em>CFH</em>, <em>CFI</em>, and <em>MCP</em> mutations demonstrated an overall recurrence rate of 60 percent, with graft failure in 92 percent of those having recurrence [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children"</a>.)</p><p>It is not entirely known why there is such disparity in the rate of recurrence among patients with different mutations. However, one of the main challenges in defining risk of recurrence is not knowing the functional consequences of the genetic variants. A potential explanation for the low recurrence rate of MCP-associated TMA is that MCP is a transmembrane protein and is potentially restored with the transplantation of a new kidney allograft. The potential mechanism was speculated to be endothelial microchimerism [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H454063776"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The clinical presentation of recurrent and de novo TMA is similar. Patients present with a microangiopathic hemolytic anemia with schistocytes on the blood smear  (<a class="graphic graphic_picture graphicRef70851" href="/d/graphic/70851.html" rel="external">picture 1</a>), thrombocytopenia, and acute kidney injury (AKI).</p><p>Typical laboratory abnormalities include an increased serum creatinine, evidence of mechanical hemolysis (increased reticulocyte percentage, reticulocytosis, and increased serum lactate dehydrogenase [LDH]), and a low platelet count. The urinalysis typically shows hematuria and only a small amount of proteinuria. Some patients may present with only an increased serum creatinine and abnormal urinalysis due to a kidney-limited lesion and without thrombocytopenia and hemolytic anemia [<a href="#rid14">14,30</a>].</p><p>Patients with recurrent TMA usually present within one year after transplantation and often within days to weeks [<a href="#rid35">35,37</a>]. In one study of 16 patients with recurrent disease, eight patients presented within one month of transplantation [<a href="#rid37">37</a>]. Patients with de novo TMA typically present within the first three months after transplantation [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H454064667"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of TMA should be suspected in any kidney transplant recipient who presents with an elevated serum creatinine after transplantation, especially if hemolytic anemia and thrombocytopenia are present. The general evaluation of kidney transplant patients who present with an increased serum creatinine is discussed separately. (See  <a class="medical medical_review" href="/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction"</a>.)</p><p>In transplant patients suspected of having TMA, a kidney allograft biopsy is not required to confirm the diagnosis of TMA, and the risk of bleeding may be prohibitive if thrombocytopenia is severe or if the patient is on a medication that increases bleeding risk. However, an allograft biopsy can be useful to elucidate the cause of TMA including antibody-mediated rejection (ABMR), viral infection (eg, cytomegalovirus [CMV]), and calcineurin inhibitor toxicity. (See  <a class="medical medical_review" href="/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction", section on 'Causes of acute allograft dysfunction'</a>.)</p><p class="headingAnchor" id="H454064889"><span class="h1">PREVENTION OF RECURRENT TMA</span></p><p class="headingAnchor" id="H1042706706"><span class="h2">Evaluation for mutations</span><span class="headingEndMark"> — </span>Prior to transplantation, we suggest that all patients with end-stage kidney disease (ESKD) due to hemolytic uremic syndrome (HUS), thrombocytopenic purpura (TTP), or other TMA be evaluated for genetic mutations that are associated with complement-mediated TMA, unless the disorder was clearly associated with a Shiga toxin-producing <em>E. coli</em> or other infection. Patients who reached ESKD due to pregnancy-associated TMA or another secondary TMA whose evolution was unusually aggressive should also be evaluated. Patients who have already been evaluated (eg, at the time of diagnosis) and found to have a mutation do not need to be retested. However, in patients who have been previously evaluated and not found to have a mutation, reevaluation for newly identified mutations and variants prior to transplant is reasonable, particularly if the initial evaluation was performed several years earlier. (See  <a class="medical medical_review" href="/d/html/6081.html" rel="external">"Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Testing for STEC infection'</a>.)</p><p>It is often difficult to accurately identify patients with TMA related to genetic mutations based upon clinical features alone. Some patients may be referred for transplant with a remote diagnosis of HUS or TTP, having started dialysis prior to the availability of complement inhibitors (eg, <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>). In addition, the transplant team may have limited information about the candidates' initial presentation and treatment. Identification of a genetic mutation clearly associated with complement-mediated TMA can confirm the diagnosis and reinforce the need for prophylactic complement inhibition after transplantation. Laboratories that offer complement genotyping for TMA can be found through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=7350" target="_blank">National Center for Biotechnology Information</a>.</p><p>If genetic testing is not feasible, we base the need for prophylactic complement inhibition after transplantation on the patient's clinical presentation. We plan for prophylactic complement inhibition in patients with a well-documented clinical presentation consistent with complement-mediated TMA or with a known family history of complement-mediated TMA. In the absence of positive genetic testing or one of these scenarios, we do <strong>not</strong> plan for prophylactic complement inhibition but rather monitor the patient closely in the immediate posttransplant period for disease recurrence. (See  <a class="medical medical_review" href="/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Clinical manifestations'</a> and <a class="local">'Prophylactic therapy with eculizumab'</a> below.)</p><p class="headingAnchor" id="H1042706718"><span class="h2">Selection of donor kidney</span><span class="headingEndMark"> — </span>For several reasons, we avoid using a living-related donor kidney for patients with TMA attributed to a genetic mutation. Although genetic analysis may be performed in donors, some patients have more than one mutation, and approximately one-third of patients with TMA have complement mutations presently unidentified [<a href="#rid9">9</a>]. Thus, a negative mutational analysis of a potential living-related donor does not guarantee freedom from mutations associated with complement-mediated TMA. In addition, nephrectomy may trigger complement-mediated TMA in the genetically susceptible donor [<a href="#rid38">38</a>].</p><p>Living-related donors may be considered in patients with factor H-autoantibody complement-mediated TMA as well as those with TMA attributed to a nongenetic cause.</p><p class="headingAnchor" id="H592627753"><span class="h2">Prophylactic therapy with eculizumab</span><span class="headingEndMark"> — </span>We initiate <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> (an antibody that targets the complement component C5) prior to transplantation in all patients with complement-mediated TMA due to a genetic deficiency or dysfunction of <em>CFH</em> or <em>CFI</em> [<a href="#rid39">39-41</a>]. We do <strong>not</strong> use eculizumab as prophylactic therapy in patients who had ESKD related to infection- or drug-associated TMA.</p><p>The optimal prophylactic regimen is not known. In patients with complement-mediated TMA related to a genetic mutation, we use the following approach:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are receiving a living-unrelated donor kidney, we administer <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> at 900 mg intravenously 24 hours prior to transplantation and on days 7, 14, and 21 following transplantation, followed by 1200 mg every two weeks thereafter. Supplemental doses (900 mg or 1200 mg) may need to be administered in settings where complement activation is known to occur, such as following surgery or when there is infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are receiving a deceased-donor kidney, we administer <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> at 900 mg intravenously on postoperative day 3 (after completion of antithymocyte globulin induction) and continue 900 mg weekly for three additional doses, followed by 1200 mg every two weeks thereafter.</p><p></p><p>The duration of <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> therapy after transplantation is unclear. It is possible that eculizumab could be discontinued with subsequent reinstitution among those who have disease recurrence [<a href="#rid42">42,43</a>]. However, no reliable marker of early disease recurrence is available. Until these data are available, we suggest continuing the drug indefinitely.</p><p>Some clinicians treat with <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> and plasmapheresis [<a href="#rid39">39,44</a>]. However, the added therapeutic benefit of plasmapheresis is unclear when using eculizumab. In addition, since eculizumab is removed with plasmapheresis, a supplemental dose must be given after each pheresis procedure. Given this, along with the costs and risks of the plasmapheresis procedure, we do <strong>not </strong>use plasmapheresis at our centers and use eculizumab alone.</p><p>Patients treated with <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> should receive prophylaxis against meningococcal infection, as discussed separately. (See <a class="local">'Prophylaxis against meningococcal infection'</a> below.)</p><p>Given the high cost of <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> therapy, some centers have tried to develop alternative transplant strategies that do not use prophylactic eculizumab. As an example, one case series from the Netherlands reported outcomes of 17 patients with complement-mediated TMA who underwent living-donor kidney transplantation without eculizumab prophylaxis [<a href="#rid45">45</a>]. All patients were at high or moderate risk for recurrent disease; 16 had pathogenic or likely pathogenic variants in factor H, C3, factor I, or membrane cofactor protein (MCP), and five had lost a previous transplant due to recurrent HUS. The transplant protocol consisted of induction therapy with <a class="drug drug_general" data-topicid="8803" href="/d/drug information/8803.html" rel="external">basiliximab</a>; triple-therapy maintenance immunosuppression with low-dose <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil targeted to a high area under the curve (AUC) level, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>; strict blood pressure control (&lt;130/80 mmHg); and early initiation of statins and angiotensin-converting enzyme inhibitors. At a median of 25 months, all patients had stable graft function (median serum creatinine 1.2 mg/dL [106 micromol/L]) without significant proteinuria; only one patient developed recurrent TMA, which responded to eculizumab treatment. These findings suggest that in patients with complement-mediated TMA, kidney transplant without prophylaxis may be feasible; however, additional longer-term studies are required to confirm the efficacy and safety of this approach.</p><p class="headingAnchor" id="H2611154358"><span class="h2">Combined kidney-liver transplantation</span><span class="headingEndMark"> — </span>In patients with ESKD due to TMA related to mutations of complement factors that are produced by the liver (eg, factor H), combined kidney-liver transplant has been used to correct the ESKD along with the underlying etiology of TMA [<a href="#rid46">46-48</a>]. However, dual-organ transplantation carries significant potential morbidity and mortality. Additionally, uncontrolled complement activation precipitated by the stress of surgery has led to widespread perioperative vascular thrombosis and graft loss as the liver allograft may not function initially to produce sufficient amounts of the complement protein. Success with combined kidney-liver transplant has improved with the use of intensive plasmapheresis in the pre- and perioperative time to restore levels of the complement protein [<a href="#rid47">47,48</a>]. Despite improvements in the results of simultaneous kidney-liver transplantation, this approach is not commonly used given the effectiveness of prophylactic complement inhibition. (See <a class="local">'Prophylactic therapy with eculizumab'</a> above.)</p><p class="headingAnchor" id="H3498057213"><span class="h1">TREATMENT OF DE NOVO TMA</span><span class="headingEndMark"> — </span>In all kidney transplant recipients with de novo TMA, we advocate inpatient admission for further evaluation and management, as discussed below.</p><p class="headingAnchor" id="H1948811165"><span class="h2">Exclusion of potentially reversible causes</span><span class="headingEndMark"> — </span>In patients who present with clinical features consistent with de novo TMA, we initially evaluate for and treat potentially reversible causes of TMA (see <a class="local">'Etiology'</a> above and <a class="local">'Treatment with eculizumab'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>In all patients who have not already been evaluated for mutations that are associated with complement-mediated TMA, we perform genetic testing to evaluate for such mutations. If the patient is found to have a genetic mutation associated with TMA, we treat with <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>. (See <a class="local">'Evaluation for mutations'</a> above and <a class="local">'Treatment with eculizumab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with a blood <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> (or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>) concentration above the therapeutic range, we reduce the dose of the calcineurin inhibitor. We do not discontinue the calcineurin inhibitor unless the blood concentration is markedly elevated (ie, tacrolimus trough level &gt;15 ng/mL or cyclosporine trough level &gt;400 ng/mL or two-hour level &gt;1500 ng/mL) [<a href="#rid32">32,49</a>]. Among patients who develop de novo TMA while on cyclosporine, switching to tacrolimus (or vice versa) is an alternative option once the acute episode of TMA resolves. If the patient is taking a mammalian (mechanistic) target of rapamycin (mTOR) inhibitor, we discontinue this agent. (See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We exclude, by polymerase chain reaction (PCR), infections including cytomegalovirus (CMV), BK virus, parvovirus, and HIV. If testing for any of these infections is positive and <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> has not yet been initiated, we treat the infection before starting eculizumab. However, if the signs and symptoms of TMA persist or there is clinical deterioration despite treatment of an infectious agent, we initiate eculizumab and continue until the infection is controlled. Similarly, if testing for any of these infections is positive and eculizumab has already been started, we continue eculizumab until the infection has been treated and TMA has resolved [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/7300.html" rel="external">"Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients", section on 'Treatment'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/7338.html" rel="external">"Kidney transplantation in adults: BK polyomavirus-associated nephropathy", section on 'Treatment'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/8330.html" rel="external">"Treatment and prevention of parvovirus B19 infection", section on 'Treatment'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See <a class="local">'Treatment with eculizumab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients who have diarrhea, we exclude infection with Shiga toxin-producing organisms (eg, <em>E. coli</em> serotypes O104:H4, O157:H7, O111; <em>Shigella</em> species) by stool studies. If stool testing for any of these organisms is positive, we administer <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> until diarrhea resolves and the patient's genetic status is known. In patients who have a genetic mutation associated with TMA, we continue eculizumab therapy as detailed below. In patients who do not have a genetic mutation, we discontinue eculizumab. (See  <a class="medical medical_review" href="/d/html/2714.html" rel="external">"Shiga toxin-producing Escherichia coli: Clinical manifestations, diagnosis, and treatment"</a> and <a class="local">'Treatment with eculizumab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We perform ADAMTS13 (<strong>A</strong> <strong>D</strong>isintegrin <strong>A</strong>nd <strong>M</strong>etalloprotease with a <strong>T</strong>hrombo<strong>S</strong>pondin type 1 motif, member <strong>13</strong>) activity testing to exclude a diagnosis of thrombotic thrombocytopenic purpura (TTP). In patients who are found to have severe ADAMTS13 deficiency (activity &lt;10 percent), we initiate treatment for TTP, as discussed separately. If the patient has already been started on <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> and genetic testing does not identify any mutations associated with TMA, we discontinue eculizumab. (See  <a class="medical medical_review" href="/d/html/1338.html" rel="external">"Diagnosis of immune TTP", section on 'ADAMTS13 testing'</a> and  <a class="medical medical_review" href="/d/html/1344.html" rel="external">"Immune TTP: Initial treatment", section on 'Overview of treatment approach'</a>.)</p><p></p><p class="headingAnchor" id="H2063821604"><span class="h2">Treatment with eculizumab</span><span class="headingEndMark"> — </span>In patients who are found to have a genetic mutation associated with TMA <strong>or </strong>have persistent symptoms and signs of TMA or progressive disease despite addressing potentially reversible causes (see <a class="local">'Exclusion of potentially reversible causes'</a> above), we treat with <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>. If eculizumab is not available, plasma exchange (1.5 volumes of fresh frozen plasma every 48 hours) can be performed [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"</a>.)</p><p class="headingAnchor" id="H3485948811"><span class="h3">Dosing and duration of therapy</span><span class="headingEndMark"> — </span>We administer <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> at 900 mg intravenously weekly for four doses, followed by 1200 mg every two weeks thereafter. The optimal duration of eculizumab treatment in patients with de novo TMA is unclear, and there is no evidence from randomized controlled trials to guide this decision. Our approach, which is based upon clinical experience at our centers, is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are at moderate to high risk for disease recurrence, we continue <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> indefinitely. Such patients include those who are found to have a pathogenic mutation in any complement protein, except in membrane cofactor protein (MCP); those with a history of recurrence in a previous allograft or biopsy-proven TMA in the native kidney (even if no genetic variant is identified); and those who have a persistent factor H autoantibody [<a href="#rid45">45</a>]. For patients who have a genetic variant of uncertain significance, treatment duration is determined on a case-by-case basis based upon functional analysis of the variant (when available).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are at low risk for disease recurrence (ie, those carrying an MCP mutation and patients who have been successfully treated for removal of factor H autoantibodies), we discontinue <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> after 6 to 12 months and monitor closely for disease recurrence.</p><p></p><p>There are limited data evaluating the discontinuation of <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> therapy in kidney transplant patients with TMA. In a case series that reported the safety of discontinuing eculizumab in 10 patients (including one kidney transplant recipient) in whom disease activity was monitored by means of home urine dipstick testing, three experienced relapse within six weeks of discontinuation [<a href="#rid51">51</a>]. All three patients who experienced relapse had pathogenic mutations in factor H but completely recovered after immediate reinitiation of treatment. Other studies in nontransplant patients have shown that eculizumab withdrawal can be considered on a case-by-case basis. These data are discussed separately. (See  <a class="medical medical_review" href="/d/html/114693.html" rel="external">"Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS", section on 'Can anti-complement therapy be stopped?'</a>.)</p><p class="headingAnchor" id="H180488655"><span class="h3">Monitoring during eculizumab therapy</span><span class="headingEndMark"> — </span>Among patients treated with <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>, we monitor hemoglobin, platelet count, and lactate dehydrogenase (LDH) daily while patients are hospitalized and then at each subsequent clinic visit. To assess the effectiveness of complement blockade, we measure total hemolytic complement (CH50) prior to each dose of eculizumab for the first four doses; patients with complete suppression should have a CH50 of &lt;10 percent. Measurement of CH50 can also confirm whether dose adjustment is indicated in patients not responding to the initial dose of eculizumab. In addition, trough serum eculizumab levels (if available) can be measured with a target level of &gt;100 mcg/mL [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Monitoring'</a>.)</p><p class="headingAnchor" id="H272376269"><span class="h3">Prophylaxis against meningococcal infection</span><span class="headingEndMark"> — </span>Treatment with <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> is associated with life-threatening and fatal meningococcal infections. Patients should receive meningococcal vaccination at least two weeks prior to initiation of eculizumab whenever possible. We ensure that patients listed for transplant with atypical hemolytic uremic syndrome (HUS) are vaccinated against meningococcus prior to transplant. We also administer daily antimicrobial prophylaxis for prevention of meningococcal infection in patients treated with eculizumab, despite vaccination, due to increased infection risk with immunosuppression. In addition, children should be vaccinated for <em>S. pneumoniae</em> and <em>Haemophilus influenza</em> type B<em> </em>(Hib) as they are at risk of developing serious infections due to these bacterial species.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1274.html" rel="external">"Treatment and prevention of meningococcal infection", section on 'Patients receiving C5 inhibitors'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H2982792227"><span class="h2">Less commonly used therapies</span><span class="headingEndMark"> — </span>Success has also been reported with intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, and conversion to a calcineurin inhibitor-free maintenance regimen using <a class="drug drug_general" data-topicid="16790" href="/d/drug information/16790.html" rel="external">belatacept</a> [<a href="#rid53">53-56</a>].</p><p class="headingAnchor" id="H464238375"><span class="h1">TREATMENT OF RECURRENT TMA</span><span class="headingEndMark"> — </span>In all patients with recurrent TMA, we advocate inpatient admission for further evaluation and management.</p><p>We treat all patients with recurrent TMA with <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>, 900 mg intravenously administered weekly for four weeks followed by 1200 mg every two weeks thereafter. The optimal duration of eculizumab treatment in patients with recurrent TMA is unclear, and there is no evidence from randomized controlled trials to guide this decision. Until these data are available, we suggest continuing the drug indefinitely.</p><p>The rationale for using <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> in patients with recurrent TMA is based upon observational data [<a href="#rid57">57-62</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In two prospective series, 37 patients (15 of whom had recurrent TMA after transplantation) received <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> for a median of 64 and 62 weeks, respectively [<a href="#rid60">60</a>]. Eculizumab increased the platelet count and decreased lactate dehydrogenase (LDH) levels in most patients and improved kidney function in approximately one-half of patients; four of five patients were able to discontinue dialysis. Plasmapheresis was discontinued in nearly all patients who were treated with this therapy at baseline. Specific data for the 15 patients with recurrent TMA were not provided.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another series from the Netherlands that included 15 patients with recurrent TMA after kidney transplantation, seven patients had recurrence early after transplant (median 3 months) while eight presented late (median 46 months) after transplant [<a href="#rid62">62</a>]. Of note, in the Netherlands, kidney transplantation for complement-mediated TMA is usually performed without <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> prophylaxis, and the drug is given only in cases of posttransplant recurrence. All patients were considered at moderate to high risk for recurrence (ie, carried a genetic variant, had a diagnosis of TMA at the time of kidney transplantation, or had lost a previous kidney transplant to TMA recurrence). Treatment with eculizumab resulted in an initial improvement or stabilization of estimated glomerular filtration rate (eGFR) in 14 patients. However, at a median of 29 months, six patients had an eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, three of whom developed graft loss. </p><p></p><p>Nearly all patients who develop recurrent TMA are assumed to have a complement-mediated process. However, other potential precipitating factors for TMA should be excluded. Exclusion of these factors should <strong>not </strong>delay the initiation of <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> therapy. (See <a class="local">'Exclusion of potentially reversible causes'</a> above.)</p><p>Monitoring during <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> therapy in patients with recurrent TMA is similar to that in patients with de novo TMA who are treated with eculizumab. All patients treated with eculizumab should receive prophylaxis against meningococcal infection, as discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See <a class="local">'Monitoring during eculizumab therapy'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See <a class="local">'Prophylaxis against meningococcal infection'</a> above.)</p><p></p><p>Plasma infusions and plasmapheresis similar to that used for the primary disease have been given, with some apparent success in selected patients [<a href="#rid2">2,12,63,64</a>]. In patients with recurrent TMA, plasmapheresis is generally reserved for patients who have TMA associated with factor H-autoantibodies or used as a temporizing measure in patients awaiting the availability of <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> therapy. (See  <a class="medical medical_review" href="/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Plasma therapy'</a>.)</p><p class="headingAnchor" id="H454064122"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Overall graft outcomes are worse in patients with recurrent TMA [<a href="#rid9">9</a>]. In one study of kidney transplant recipients whose end-stage kidney disease (ESKD) was due to TMA, the one- and five-year allograft survival rates were lower for those who developed recurrent disease compared with those who did not (33 versus 57 percent at one year and 19 versus 57 percent at five years) [<a href="#rid37">37</a>]. However, these data were obtained prior to the availability of <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>.</p><p class="headingAnchor" id="H1585956290"><span class="h1">RETRANSPLANTATION</span><span class="headingEndMark"> — </span>Retransplantation is a potential option in selected patients with recurrent or de novo TMA after transplant. At our centers, we consider retransplantation in patients with graft loss due to complement-mediated TMA prior to the availability of <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> and in those with de novo TMA related to infection or medications. As discussed above (see <a class="local">'Prophylactic therapy with eculizumab'</a> above), prophylactic eculizumab is warranted in those with a genetic risk but may not be necessary for those with an infectious or medication-related cause of the TMA. However, these patients should be closely monitored posttransplant for TMA recurrence with the initiation of eculizumab if clinically indicated.</p><p class="headingAnchor" id="H2366700523"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110754.html" rel="external">"Society guideline links: Kidney transplantation"</a> and  <a class="medical medical_review" href="/d/html/1338.html" rel="external">"Diagnosis of immune TTP"</a> and  <a class="medical medical_society_guidelines" href="/d/html/117846.html" rel="external">"Society guideline links: Thrombotic microangiopathies (TTP, HUS, and related disorders)"</a>.)</p><p class="headingAnchor" id="H764474882"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology </strong>– Thrombotic microangiopathy (TMA) is characterized by mechanical hemolytic anemia, thrombocytopenia, and kidney function impairment that occasionally progresses to end-stage kidney disease (ESKD), requiring either dialysis or transplantation. Among patients with ESKD due to TMA who undergo transplantation, TMA commonly recurs, particularly among patients with TMA that is related to a genetic mutation. Less commonly, patients who undergo kidney transplantation for other causes of ESKD may develop de novo TMA due to immunosuppressive drugs, ischemia reperfusion injury, viral infections, and antibody-mediated rejection (ABMR). (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation and diagnosis </strong>– The clinical presentation of recurrent and de novo TMA is similar. Patients present with a microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI). Typical laboratory abnormalities include an increased serum creatinine, evidence of hemolysis, and a low platelet count. The urinalysis typically shows hematuria and only a small amount of proteinuria. Some patients may present with only an increased serum creatinine and abnormal urinalysis due to the kidney lesion associated with TMA and without thrombocytopenia and hemolytic anemia. Biopsy whenever possible may confirm the diagnosis as well as underlying etiologies. (See <a class="local">'Clinical presentation'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of recurrent TMA</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prior to transplantation, all patients with ESKD due to TMA should be evaluated for genetic mutations that are associated with complement-mediated TMA, unless the disorder was caused by a Shiga toxin-producing <em>Escherichia coli</em> or other infection. (See <a class="local">'Evaluation for mutations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among all patients with complement-mediated TMA, we advise using a living-unrelated donor kidney or a deceased-donor kidney rather than a living-related donor kidney. (See <a class="local">'Selection of donor kidney'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For all patients with complement-mediated TMA due to genetic deficiency or dysfunction of complement factor H (<em>CFH</em>) or complement factor I (<em>CFI</em>), we suggest prophylactic treatment with <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> rather than plasmapheresis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We do <strong>not</strong> use eculizumab as prophylactic therapy in patients who had ESKD related to infection- or drug-associated TMA. (See <a class="local">'Prophylactic therapy with eculizumab'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of de novo TMA </strong>– Among all patients with de novo TMA, we evaluate for and treat all potentially reversible causes. Patients who have not already been evaluated for mutations that are associated with complement-mediated TMA should undergo genetic testing to evaluate for such mutations. In patients who are found to have a genetic mutation associated with TMA <strong>or </strong>have persistent symptoms and signs of TMA or progressive disease despite addressing potentially reversible causes, we treat with <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>. If eculizumab is not available, plasma exchange can be performed. (See <a class="local">'Treatment of de novo TMA'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of recurrent TMA </strong>– For all patients who develop recurrent TMA, we suggest treating with <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> rather than plasmapheresis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The optimal duration of eculizumab treatment in patients with recurrent TMA is unclear. In addition, other potential precipitating factors for TMA, such as medications and infections, should be excluded. (See <a class="local">'Treatment of recurrent TMA'</a> above.)</p><p></p><p class="headingAnchor" id="H346557007"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Mohamed H Sayegh, MD, and Christina Klein, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Miller RB, Burke BA, Schmidt WJ, et al. Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report. Nephrol Dial Transplant 1997; 12:1425.</a></li><li><a class="nounderline abstract_t">Zarifian A, Meleg-Smith S, O'donovan R, et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999; 55:2457.</a></li><li><a class="nounderline abstract_t">Ruggenenti P. Post-transplant hemolytic-uremic syndrome. Kidney Int 2002; 62:1093.</a></li><li><a class="nounderline abstract_t">Kwon O, Hong SM, Sutton TA, Temm CJ. Preservation of peritubular capillary endothelial integrity and increasing pericytes may be critical to recovery from postischemic acute kidney injury. Am J Physiol Renal Physiol 2008; 295:F351.</a></li><li><a class="nounderline abstract_t">Murer L, Zacchello G, Bianchi D, et al. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. J Am Soc Nephrol 2000; 11:1132.</a></li><li><a class="nounderline abstract_t">Waiser J, Budde K, Rudolph B, et al. De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. Am J Kidney Dis 1999; 34:556.</a></li><li><a class="nounderline abstract_t">Olie KH, Goodship TH, Verlaak R, et al. Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir. Am J Kidney Dis 2005; 45:e12.</a></li><li><a class="nounderline abstract_t">Ardalan MR, Shoja MM, Tubbs RS, et al. Postrenal transplant hemophagocytic lymphohistiocytosis and thrombotic microangiopathy associated with parvovirus b19 infection. Am J Transplant 2008; 8:1340.</a></li><li><a class="nounderline abstract_t">Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:1676.</a></li><li><a class="nounderline abstract_t">Zuber J, Le Quintrec M, Sberro-Soussan R, et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011; 7:23.</a></li><li><a class="nounderline abstract_t">Le Quintrec M, Lionet A, Kamar N, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008; 8:1694.</a></li><li><a class="nounderline abstract_t">Agarwal A, Mauer SM, Matas AJ, Nath KA. Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: current concepts and management. J Am Soc Nephrol 1995; 6:1160.</a></li><li><a class="nounderline abstract_t">Miller BW, Hmiel SP, Schnitzler MA, Brennan DC. Cyclosporine as cause of thrombotic microangiopathy after renal transplantation. Am J Kidney Dis 1997; 29:813.</a></li><li><a class="nounderline abstract_t">Schwimmer J, Nadasdy TA, Spitalnik PF, et al. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 2003; 41:471.</a></li><li><a class="nounderline abstract_t">Karthikeyan V, Parasuraman R, Shah V, et al. Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant 2003; 3:1289.</a></li><li><a class="nounderline abstract_t">Holman MJ, Gonwa TA, Cooper B, et al. FK506-associated thrombotic thrombocytopenic purpura. Transplantation 1993; 55:205.</a></li><li><a class="nounderline abstract_t">Trimarchi HM, Truong LD, Brennan S, et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation 1999; 67:539.</a></li><li><a class="nounderline abstract_t">Pham PT, Peng A, Wilkinson AH, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis 2000; 36:844.</a></li><li><a class="nounderline abstract_t">Kiykim AA, Ozer C, Yildiz A, et al. Development of transplant renal artery thrombosis and signs of haemolytic-uraemic syndrome following the change from cyclosporin to tacrolimus in a renal transplant patient. Nephrol Dial Transplant 2004; 19:2653.</a></li><li><a class="nounderline abstract_t">Sartelet H, Toupance O, Lorenzato M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005; 5:2441.</a></li><li><a class="nounderline abstract_t">Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129.</a></li><li><a class="nounderline abstract_t">Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1998; 177:48.</a></li><li><a class="nounderline abstract_t">Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997; 76:369.</a></li><li><a class="nounderline abstract_t">Frem GJ, Rennke HG, Sayegh MH. Late renal allograft failure secondary to thrombotic microangiopathy-human immunodeficiency virus nephropathy. J Am Soc Nephrol 1994; 4:1643.</a></li><li><a class="nounderline abstract_t">Hochstetler LA, Flanigan MJ, Lager DJ. Transplant-associated thrombotic microangiopathy: the role of IgG administration as initial therapy. Am J Kidney Dis 1994; 23:444.</a></li><li><a class="nounderline abstract_t">Pham PT, Danovitch GM, Wilkinson AH, et al. Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation 2002; 74:1077.</a></li><li><a class="nounderline abstract_t">Canaud G, Bienaimé F, Noël LH, et al. Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant 2010; 10:2051.</a></li><li><a class="nounderline abstract_t">Satoskar AA, Pelletier R, Adams P, et al. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant 2010; 10:1804.</a></li><li><a class="nounderline abstract_t">Bascuñana A, Mijaylova A, Vega A, et al. Thrombotic Microangiopathy in a Kidney Transplant Patient With COVID-19. Kidney Med 2021; 3:124.</a></li><li><a class="nounderline abstract_t">Hebert D, Sibley RK, Mauer SM. Recurrence of hemolytic uremic syndrome in renal transplant recipients. Kidney Int Suppl 1986; 19:S51.</a></li><li><a class="nounderline abstract_t">Artz MA, Steenbergen EJ, Hoitsma AJ, et al. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation 2003; 76:821.</a></li><li><a class="nounderline abstract_t">Oyen O, Strøm EH, Midtvedt K, et al. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. Am J Transplant 2006; 6:412.</a></li><li><a class="nounderline abstract_t">Ducloux D, Rebibou JM, Semhoun-Ducloux S, et al. Recurrence of hemolytic-uremic syndrome in renal transplant recipients: a meta-analysis. Transplantation 1998; 65:1405.</a></li><li><a class="nounderline abstract_t">Quan A, Sullivan EK, Alexander SR. Recurrence of hemolytic uremic syndrome after renal transplantation in children: a report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 2001; 72:742.</a></li><li><a class="nounderline abstract_t">Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006; 1:88.</a></li><li><a class="nounderline abstract_t">Frémeaux-Bacchi V, Arzouk N, Ferlicot S, et al. Recurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism. Am J Transplant 2007; 7:2047.</a></li><li><a class="nounderline abstract_t">Lahlou A, Lang P, Charpentier B, et al. Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Coopératif de l'Ile-de-France (GCIF). Medicine (Baltimore) 2000; 79:90.</a></li><li><a class="nounderline abstract_t">Loirat C, Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant 2008; 12:619.</a></li><li><a class="nounderline abstract_t">Nester C, Stewart Z, Myers D, et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011; 6:1488.</a></li><li><a class="nounderline abstract_t">Zimmerhackl LB, Hofer J, Cortina G, et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010; 362:1746.</a></li><li><a class="nounderline abstract_t">Levi C, Frémeaux-Bacchi V, Zuber J, et al. Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence. Transplantation 2017; 101:2924.</a></li><li><a class="nounderline abstract_t">van den Brand JA, Verhave JC, Adang EM, Wetzels JF. Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 2017; 32:i115.</a></li><li><a class="nounderline abstract_t">Java A. Peri- and Post-operative Evaluation and Management of Atypical Hemolytic Uremic Syndrome (aHUS) in Kidney Transplantation. Adv Chronic Kidney Dis 2020; 27:128.</a></li><li><a class="nounderline abstract_t">Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012; 12:3337.</a></li><li><a class="nounderline abstract_t">Duineveld C, Verhave JC, Berger SP, et al. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series. Am J Kidney Dis 2017; 70:770.</a></li><li><a class="nounderline abstract_t">Saland JM, Ruggenenti P, Remuzzi G, Consensus Study Group. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009; 20:940.</a></li><li><a class="nounderline abstract_t">Jalanko H, Peltonen S, Koskinen A, et al. Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. Am J Transplant 2008; 8:216.</a></li><li><a class="nounderline abstract_t">Saland JM, Emre SH, Shneider BL, et al. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant 2006; 6:1948.</a></li><li><a class="nounderline abstract_t">Bren A, Pajek J, Grego K, et al. Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy. Transplant Proc 2005; 37:1889.</a></li><li><a class="nounderline abstract_t">Java A, Edwards A, Rossi A, et al. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature. Transpl Int 2015; 28:1121.</a></li><li><a class="nounderline abstract_t">Ardissino G, Possenti I, Tel F, et al. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis 2015; 66:172.</a></li><li><a class="nounderline abstract_t">Wong E, Challis R, Sheerin N, et al. Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology 2016; 221:715.</a></li><li><a class="nounderline abstract_t">Ashman N, Chapagain A, Dobbie H, et al. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. Am J Transplant 2009; 9:424.</a></li><li><a class="nounderline abstract_t">Midtvedt K, Bitter J, Dørje C, et al. Belatacept as immunosuppression in patient with recurrence of hemolytic uremic syndrome after renal transplantation. Transplantation 2009; 87:1901.</a></li><li><a class="nounderline abstract_t">Watt T, Warshaw B, Katzenstein HM. Atypical hemolytic uremic syndrome responsive to steroids and intravenous immune globulin. Pediatr Blood Cancer 2009; 53:90.</a></li><li><a class="nounderline abstract_t">Lionet A, Provôt F, Glowacki F, et al. A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab. NDT Plus 2009; 2:458.</a></li><li><a class="nounderline abstract_t">Larrea CF, Cofan F, Oppenheimer F, et al. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010; 89:903.</a></li><li><a class="nounderline abstract_t">Nürnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360:542.</a></li><li><a class="nounderline abstract_t">Châtelet V, Lobbedez T, Frémeaux-Bacchi V, et al. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transplant Proc 2010; 42:4353.</a></li><li><a class="nounderline abstract_t">Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368:2169.</a></li><li><a class="nounderline abstract_t">Davin JC, Gracchi V, Bouts A, et al. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 2010; 55:708.</a></li><li><a class="nounderline abstract_t">Duineveld C, Bouwmeester RN, Wijnsma KL, et al. Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation. Kidney Int Rep 2023.</a></li><li><a class="nounderline abstract_t">Springate J, Fildes R, Anthone S, et al. Recurrent hemolytic syndrome after renal transplantation. Transplant Proc 1988; 20:559.</a></li><li><a class="nounderline abstract_t">Stevenson JA, Dumke A, Glassock RJ, et al. Thrombotic microangiopathy: recurrence following renal transplant and response to plasma infusion. Am J Nephrol 1982; 2:227.</a></li></ol></div><div id="topicVersionRevision">Topic 7350 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9249780" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10354295" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cyclosporine-associated thrombotic microangiopathy in renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12164897" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Post-transplant hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18562634" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Preservation of peritubular capillary endothelial integrity and increasing pericytes may be critical to recovery from postischemic acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10820178" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10469868" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696434" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18522549" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Postrenal transplant hemophagocytic lymphohistiocytosis and thrombotic microangiopathy associated with parvovirus b19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19846853" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21102542" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : New insights into postrenal transplant hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18557729" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589282" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: current concepts and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9159323" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cyclosporine as cause of thrombotic microangiopathy after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12552512" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14510703" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7678357" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : FK506-associated thrombotic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071024" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : FK506-associated thrombotic microangiopathy: report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11007689" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cyclosporine and tacrolimus-associated thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15388824" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Development of transplant renal artery thrombosis and signs of haemolytic-uraemic syndrome following the change from cyclosporin to tacrolimus in a renal transplant patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162193" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337603" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : VEGF inhibition and renal thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9419169" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9352739" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8011972" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Late renal allograft failure secondary to thrombotic microangiopathy-human immunodeficiency virus nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8128949" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Transplant-associated thrombotic microangiopathy: the role of IgG administration as initial therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12438949" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20883539" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20659088" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33319192" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Thrombotic Microangiopathy in a Kidney Transplant Patient With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3528626" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Recurrence of hemolytic uremic syndrome in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14501861" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16426329" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9625029" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Recurrence of hemolytic-uremic syndrome in renal transplant recipients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11544443" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Recurrence of hemolytic uremic syndrome after renal transplantation in children: a report of the North American Pediatric Renal Transplant Cooperative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699195" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17617869" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Recurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10771707" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Coopératif de l'Ile-de-France (GCIF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18482212" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hemolytic uremic syndrome recurrence after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21617085" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20445192" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28858176" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28391343" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32553245" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Peri- and Post-operative Evaluation and Management of Atypical Hemolytic Uremic Syndrome (aHUS) in Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22958221" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28821363" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19092117" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Liver-kidney transplantation to cure atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17973958" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16889549" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15919494" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25864519" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26111906" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26037115" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19120084" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19543075" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Belatacept as immunosuppression in patient with recurrence of hemolytic uremic syndrome after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19301397" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Atypical hemolytic uremic syndrome responsive to steroids and intravenous immune globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25984036" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20386298" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179328" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Eculizumab for atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21168697" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23738544" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19854549" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3289199" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Recurrent hemolytic syndrome after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6756148" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Thrombotic microangiopathy: recurrence following renal transplant and response to plasma infusion.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
